Report Highlights
The global market for women’s health therapeutics was worth nearly $18.3 billion in 2012. The market is expected to increase from nearly $19 billion in 2013 to nearly $22.5 billion by 2018, a compound annual growth rate (CAGR) of 3.5% for the five-year period, 2013 to 2018.
Report Includes
- An overview of the global therapeutics for women's health market.
- Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
- Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
- Detailed analysis of annual costs as well discussion on branded vs. generics.
- Specifics on market factors such as drivers, restraints, competition, and market shares.
- Information on marketed as well as pipeline drugs and therapies.
Report Scope
This report is an analytical business tool whose primary purpose is to describe the thorough evaluation of the global market for women's health therapeutics. The format of the study is organized around the following topics:
- Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause and polycystic ovary syndrome (PCOS).
- Disease incidence and prevalence.
- Regulatory structure.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2018.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status and clinical trials.
- Observations and conclusions regarding the future of women's health therapeutics market.
- Profiles of market participants and associations.
Analyst Credentials
Dr. Ritu Thakur is an independent consultant based in New Delhi, India with 10+ years of experience in consulting, business/market research, business & report writing, analytics, content development & management and translation. She has prior work experience with Panasonic (Healthcare Division), GlobalData (U.K.-based market research firm) and several other development stage/early stage companies including Biovo, Diabesity, Medibrane, ScaleThings, EndoGI, Ramot Biomedical Eng and NeverWet. In her previous assignments, she has delivered hundreds of small to large scale custom projects on pharmaceutical, medical and biotechnology subjects. She has developed reports for BCC Research for more than four years and has worked as an author for healthcare and other related industries such as pharmaceuticals, biotechnology and medical devices.
Related Reports
Human Reproductive Technologies: Products and Global Markets
The total market for reproductive technologies and products is estimated to achieve revenues of nearly $16.1 billion in 2013. In 2018, the forecasted revenues will likely reach $19.6 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%.
Therapies and Diagnostics for Uterine Cancer
The global market for uterine cancer treatments and diagnostics reached $17.4 billion in 2012. This market is expected to grow to nearly $17.8 billion in 2013 and then to nearly $21.6 billion in 2018, a compound annual growth rate (CAGR) of 3.9% over the five-year period from 2013 to 2018.
Therapies and Diagnostics for Cervical Cancer
The global cervical cancer market for drugs and diagnostics was $11.3 billion in 2012 and is expected to grow from $11.6 billion in 2013 to $15.6 billion by 2018, a compound annual growth rate (CAGR) of 6.1%.
Therapies and Diagnostics for Ovarian Cancer
The global ovarian cancer drug and diagnostic market was valued at $16.1 billion in 2012. The market is predicted to grow to $18.7 billion in 2013 and $34.6 billion by 2018, a compound annual growth rate (CAGR) of 13.1% between 2013 and 2018.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Chromatography in Pharmaceuticals and Biotechnology: Global Markets
The global market for chromatography in pharmaceuticals and biotechnology is estimated to grow from $13.3 billion in 2025 to reach $19.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.4% from 2025 to 2030.
Genome Editing: Technologies and Global Markets
The global market for genome editing is expected to grow from $10.8 billion in 2025 and is projected to reach $23.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.9% during the forecast period of 2025 to 2030.
Global Assisted Reproductive Technologies Market
The report provides an analysis of the global assisted reproductive technologies market and analyzes market trends. Using 2024 as the base year, the report provides estimated market data for 2025 through 2030. The market in this report is segmented into procedure, product, end user, and region. The report focuses on the significant trends, challenges and technological advancements that alter the market and vendor landscape.
Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market
The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.
Global DNA Forensics Market
The global market for DNA forensics is projected to grow from an estimated $3.3 billion in 2025 to $4.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030.
Report Highlights
- The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
- The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
- Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%.
Report Highlights
-
The total U.S. market for new therapeutics and diagnostics for women’s disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an AAGR (average annual growth rate) of 10.3%.
-
Treatments for cancers specific to women will rise the fastest, at an AAGR of 12.6% and will lead revenues in 2009.
-
Reproductive-related therapies and diagnostics currently represent the largest market segment, but, rising at an AGR of 8.4%, will lag slightly by 2009.
-
Treatments for gynecological diseases and infections and for rheumatoid arthritis and osteoporosis also represent large market segments.
Report Highlights
-
The total current U.S. market for new therapeutics and diagnostics for women's disorders in 1999 reached $16.9 billion at the manufacturers' level. The growing numbers of women combined with the growing trend to take an active role in healthcare has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $31.9 billion, growing at an average annual rate of 8.7%.
-
The reproductive-related therapeutics and diagnostics holds the largest market revenues position representing 31.9% and accounting for $5.4 billion of the total in 1999. Large numbers of women in the baby boomer age group, coupled with large numbers of the mini-boomers (daughters of the baby boomer generation), contributed to the reproductive-related therapeutics and diagnostics' dominate role in 1999. It is anticipated that the reproductive-related therapeutics and diagnostics will remain the largest market share throughout the forecast period as it crosses $10 billion by 2005.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More